Healthcare IT In the cloud: predicting threats, protecting patient data

whitePaper | December 6, 2022

Cybersecurity has become one of the most complex and urgent issues facing the healthcare industry. The number of cyber attacks continues to grow, and attackers are getting even more sophisticated at compromising systems.

whitePaper | March 4, 2020

Health leaders must understand the benefits of their investments in performance improvement projects and the impact on the organization. The traditional approach is most often to measure ROI (return on investment) and, while clearly measurable, is most often related to cost savings or increased revenue and can leave you with an incomplete story. Incorporating VOI (value on investment) enables you to quantify the intangible benefits of your projects and activities making the combination of the two a more robust indicator of project success.

whitePaper | November 17, 2021

The pandemic hit the healthcare industry hard, but it also weakened the cybersecurity defenses of most providers, making them far more vulnerable to threats such as ransomware. This report, covered across national news, is considered the most significant actionable cybersecurity research over the past several years because it also documents the severe impact on patient care. This executive summary includes critical areas that providers can address starting today.

whitePaper | June 21, 2022

To improve outcomes for cancer patients and take advantage of the groundbreaking scientific and technological progress made in oncology prevention, diagnosis, therapy, and care over recent years, it is of crucial importance to ensure all patients with cancer have a role and an ongoing dialogue with the healthcare team.

whitePaper | September 26, 2022

Healthcare is at a data tipping point. The adoption of a wide variety of information technology (IT) systems has given hospitals and health systems a massive amount of data, along with the power to use that data to enhance patient care, streamline operations and reduce costs.

whitePaper | January 27, 2023

Big Pharma conducted most of its early-stage clinical studies in the West before incorporating Asian locations in later phase studies. Though the Asian region had limited experience in the beginning, over time, researchers’ and local regional experience.